The FDA opened an investigation into Novartis’ Zolgensma after reports of cancer in patients receiving the spinal muscular atrophy gene therapy. The inquiry was triggered by disclosures from Novartis and is framed by the agency as involving a serious risk, prompting heightened scrutiny of post-marketing safety. For biotech and gene-therapy developers, the move reinforces how quickly rare but high-impact events can drive regulatory follow-up—especially for therapies intended for infants and children. Industry stakeholders will watch for whether the FDA requests additional analyses, cohort comparisons, or enhanced reporting requirements. The investigation’s trajectory could influence risk-benefit discussions, labeling updates, and future trial monitoring approaches for AAV-based platform programs.